Medicinal chemistry is a discipline grounded in quantitative data. Decision-making relies on the correct use and presentation of values derived from experimental and theoretical methods. Biological assays dominate early drug discovery and frequently provide critical guidance for the optimization of a drug candidate.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by David E. Heppner
Undergraduate Student Perspectives on Medicinal Chemistry and Drug Discovery Research Click to copy article link Article link copied!
The education of future scientists and healthcare professionals is shaped through many avenues, but immersive research experiences offer unique opportunities that expose trainees to the realities of the scientific process.
Structural Biology Enabling Drug Discovery
Structural biology continues to profoundly impact medicinal chemistry by providing valuable insights into molecular recognition, target engagement, and mechanisms of action that accelerate drug discovery. This Special Issue, jointly curated within the Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters, showcases contributions from a global community of researchers leveraging structural techniques and insights to advance the discovery and optimization of new therapeutic agents.
Structural Biology Enabling Drug Discovery
Journal of Medicinal Chemistry Cite this: J. Med. Chem. 2025, XXXX, XXX Click to copy citationCitation copied! . This publication is available under these Terms of Use. Learn about these metrics Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.
Drug Discovery and Development Faces an Ominous Future from NIH Indirect Costs Rate Cuts
On February 7, 2025, the Office of the Director of the National Institutes of Health (NIH) issued a Supplemental Guidance to the 2024 NIH Grants Policy Statement, stating: “For all existing grants to [Institutions of Higher Education], retroactive to the date of issuance of this Supplemental Guidance, award recipients are subject to a 15 percent indirect cost rate.” (1) This reduction in the indirect cost (IDC) rate is a considerable cut in financial support for critical overhead and...
Drug Discovery and Development Faces an Ominous Future from NIH Indirect Costs Rate Cuts
On February 7, 2025, the Office of the Director of the National Institutes of Health (NIH) issued a Supplemental Guidance to the 2024 NIH Grants Policy Statement, stating: “For all existing grants to [Institutions of Higher Education], retroactive to the date of issuance of this Supplemental Guidance, award recipients are subject to a 15 percent indirect cost rate.” (1) This reduction in the indirect cost (IDC) rate is a considerable cut in financial support for critical overhead and...
Ascertaining a Structural Basis in Drug Discovery and Development
Special Issue Published as part of Journal of Medicinal Chemistry special issue “Structural Biology in Drug Discovery and Development”. Medicinal chemists frequently leverage a “structural basis” to rationalize the activity of small molecules and guide structure-based optimization in drug discovery.
Ascertaining a Structural Basis in Drug Discovery and Development
Special Issue Published as part of Journal of Medicinal Chemistry special issue “Structural Biology in Drug Discovery and Development”. Medicinal chemists frequently leverage a “structural basis” to rationalize the activity of small molecules and guide structure-based optimization in drug discovery.
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors
Molecules that possess the ability to form irreversible covalent bonds with their targets are well established in drug development with various examples clinically approved, (1,2) and are featured as the theme of an ACS cross-journal virtual special issue. (3) The formation of a permanently bound complex results in strong pharmacological responses that arise from a prolonged residence time.
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors
Molecules that possess the ability to form irreversible covalent bonds with their targets are well established in drug development with various examples clinically approved, (1,2) and are featured as the theme of an ACS cross-journal virtual special issue. (3) The formation of a permanently bound complex results in strong pharmacological responses that arise from a prolonged residence time.
Structural Biology in Drug Discovery and Development: Call for Papers
Figures References This publication has no figures. This article references 8 other publications. 1 Arrowsmith, C. H. Structure-guided drug discovery: back to the future. Nat. Struct. Mol. Biol. 2024, 31 (3), 395– 396, DOI: 10.1038/s41594-024-01244-3 There is no corresponding record for this reference. 2 Bancet, A.; Raingeval, C.; Lomberget, T.; Le Borgne, M.; Guichou, J.-F.; Krimm, I. Fragment Linking Strategies for Structure-Based Drug Design. J. Med. Chem.
Structural Biology in Drug Discovery and Development: Call for Papers
Figures References This publication has no figures. This article references 8 other publications. 1 Arrowsmith, C. H. Structure-guided drug discovery: back to the future. Nat. Struct. Mol. Biol. 2024, 31 (3), 395– 396, DOI: 10.1038/s41594-024-01244-3 There is no corresponding record for this reference. 2 Bancet, A.; Raingeval, C.; Lomberget, T.; Le Borgne, M.; Guichou, J.-F.; Krimm, I. Fragment Linking Strategies for Structure-Based Drug Design. J. Med. Chem.
Structural analysis of the macrocyclic inhibitor BI‐4020 binding to EGFR kinase
Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Filename Description cmdc202300343-s1-Supporting_Information.pdf857.7 KB Supplementary
Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors - Nature Communications
Study protocol DFCI IRB and the Hospital Sírio-Libanês IRB approved the protocol for this study. Patients provided written informed consent according to CARE guidelines and in compliance with the Declaration of Helsinki principles. Cell lines and drugs The PC-9 NSCLC cell line harboring EGFR mutant (del E746_A750) was originally established in Tokyo Medical University and obtained from Dr. Nishio Kazuto (Kindai University, Osaka, Japan) in 2005, and confirmed by fingerprinting.
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors - Nature Communications
|
By Tyler S Beyett, Ciric To, David E. Heppner, Anna M Schmoker, David Scott Verified, Nathanael S. Gray, Michael Eck
|
Nature
Verified
Abstract Lung cancer is frequently caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric EGFR inhibitors offer promise as the next generation of therapeutics, as they are unaffected by common ATP-site resistance mutations and synergize with the drug osimertinib. Here, we examine combinations of ATP-competitive and allosteric inhibitors to better understand the molecular basis for synergy.
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer - Nature Cancer
Abstract Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant lung cancer, although drug resistance eventually develops. Allosteric EGFR inhibitors, which bind to a different EGFR site than existing ATP-competitive EGFR TKIs, have been developed as a strategy to overcome therapy-resistant EGFR mutations.
Rapid Decay of the Native Intermediate in the Metallooxidase Fet3p Enables Controlled FeII Oxidation for Efficient Metabolism
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Am. Chem. Soc. 2020, XXXX, XXX RETURN TO ARTICLES ASAPPREVArticleNEXT Stephen M. Jones, David E. Heppner, Kenny Vu, Daniel J. Kosman*, and Edward I. Solomon* LEARN ABOUT THESE METRICS Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.
Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Med. Chem. 2020, XXXX, XXX Learn More about expanded access to ACS Publications research. RETURN TO ARTICLES ASAPPREVArticleNEXT David E. Heppner David E.
A driving test for oncogenic mutations
David E. Heppner, Tyler S. Beyett and Michael J. Eck1 From the Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115 ↵1 To whom correspondence should be addressed. E-mail: eck{at}crystal.harvard.edu. Edited by Eric R.
Direct cysteine sulfenylation drives activation of the Src kinase
To identify the redox-active Src cysteine residues that are susceptible to sulfenylation by H O , we utilized various sulfenic acid-selective trapping reagents to assess H O -induced cysteine modifications in recombinant Src using liquid chromatography-tandem mass spectrometry (LC–MS/MS).
The NADPH Oxidases DUOX1 and NOX2 Play Distinct Roles in Redox Regulation of Epidermal Growth Factor Receptor Signaling
The epidermal growth factor receptor (EGFR) plays a critical role in regulating airway epithelial homeostasis and responses to injury. Activation of EGFR is regulated by redox-dependent processes involving reversible cysteine oxidation by reactive oxygen species (ROS) and involves both ligand-dependent and -independent mechanisms, but the precise source(s) of ROS and the molecular mechanisms that control tyrosine kinase activity are incompletely understood.
The NADPH oxidases DUOX1 and NOX2 Play Distinct Roles in Redox Regulation of Epidermal Growth Factor Receptor Signaling
The epidermal growth factor receptor (EGFR) plays a critical role in regulating airway epithelial homeostasis and responses to injury. Activation of EGFR is regulated by redox-dependent processes involving reversible cysteine oxidation by reactive oxygen species (ROS) and involves both ligand-dependent and -independent mechanisms, but the precise source(s) of ROS and the molecular mechanisms that control tyrosine kinase activity are incompletely understood.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with David E.
Contact David E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack